Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Biotechnology Market Value Set to Reach $2,667.36 Billion
The global biotechnology market is projected to reach $550.83 billion in 2024 and $2667.36 billion by 2034, driven by advancements in synthetic biology, CRISPR, and genomic sequencing. North America is expected to lead, with a revenue of $231.68 billion in 2024, due to established agricultural biotechnology and a robust GMO framework. Key players include Johnson & Johnson, Roche, Pfizer, and Novartis.
AstraZeneca, Amgen Claim Late-Stage Win in Chronic Rhinosinusitis but Analyst Flags ...
AstraZeneca and Amgen's Tezspire met primary endpoint in Phase III WAYPOINT study, showing significant efficacy in chronic rhinosinusitis with nasal polyps. Tezspire reduced nasal polyps size and congestion with a consistent safety profile. Analysts note potential regulatory risks due to single study evaluation, contrasting with Sanofi and Regeneron's Dupixent, which had two pivotal studies. AstraZeneca and Amgen plan to share data with regulatory authorities and present at a medical congress.
Breaking Down Biosimilar Barriers: The Patent System
Biosimilars face barriers in the US, including the patent system, interchangeability, and PBM policies. The 'patent dance' under the BPCIA aims to expedite biosimilar market entry but is criticized for being cumbersome. Patent litigation often leads to biosimilar launch delays, as seen with adalimumab and ustekinumab biosimilars. Policy reforms, such as the Affordable Prescriptions for Patients Act, aim to address these issues but face legislative challenges.
Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours
Palleon Pharmaceuticals reports Phase I/II study results of E-602 with cemiplimab for PD-(L)1-resistant solid tumours. The combination therapy was well-tolerated, with no dose-limiting toxicities. Patients with tumour hypersialylation showed better clinical outcomes, including one partial response and six stabilisations. Tumour desialylation and immune modulation were observed in hypersialylation cases. E-602 is the first candidate in a new class of therapeutics targeting glyco-immunology.
Roflumilast cream 0.15% addresses unmet needs of adults, children with atopic dermatitis
Roflumilast cream 0.15% showed high efficacy in treating mild to moderate atopic dermatitis in patients aged 6 years and older, with more patients achieving a validated IGA-AD score of 0/1 and minimal application site irritation.
MAIA Biotechnology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial ...
MAIA Biotechnology, Inc. filed a Form 8-K on November 8, 2024, detailing new efficacy data from its Phase 2 THIO-101 clinical trial, a business presentation, and a summary of its partnership with Regeneron, all posted on its website.
Tezspire succeeds in Phase III nasal polyps trial
AstraZeneca and Amgen's Tezspire met co-primary endpoints in a Phase III trial for chronic rhinosinusitis with nasal polyps, showing significant reduction in nasal polyps and congestion. Tezspire, a TSLP inhibiting monoclonal antibody, also received FDA breakthrough therapy designation for COPD. The therapy competes with Sanofi and Regeneron's Dupixent, which generated €10.7bn in sales in 2022. Both Tezspire and Dupixent are projected to see increased sales by 2030.
OncoResponse reports data of Phase I solid tumour treatment trial
OncoResponse's Phase I trial of OR502, an anti-LILRB2 antibody, showed safety and promising early efficacy in treating advanced solid tumours, with a 65% disease control rate. The study assessed OR502 both alone and with cemiplimab, identifying an optimal dose for further trials in melanoma and NSCLC patients.
EMA approves Sanofi/Regeneron's Dupixent for young EoE patients
EMA approves Sanofi/Regeneron’s Dupixent for EoE in children aged 1-11, weighing at least 15kg, based on EoE KIDS trial results. Dupixent is the first approved treatment for these young patients, with efficacy and safety consistent with its profile in adolescents and adults.
© Copyright 2024. All Rights Reserved by MedPath